Comparison 11. Peripartum/postnatal prophylaxis (caesarean): LMWH versus LMWH (different types).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
11.1 Symptomatic thromboembolic events	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
11.1.1 Dalteparin versus enoxaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.1.2 Dalteparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.1.3 Enoxaparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.2 Symptomatic pulmonary embolism	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
11.2.1 Dalteparin versus enoxaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.2.2 Dalteparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.2.3 Enoxaparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.3 Symptomatic deep vein thrombosis	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
11.3.1 Dalteparin versus enoxaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.3.2 Dalteparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.3.3 Enoxaparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.4 Bleeding episodes (excessive bruising)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
11.4.1 Dalteparin versus enoxaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.4.2 Dalteparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.4.3 Enoxaparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.5 Adverse effects not sufficient to stop treatment	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
11.5.1 Dalteparin versus enoxaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.5.2 Dalteparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
11.5.3 Enoxaparin versus tinzaparin	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable